.

18 December 2020

Dr. Vladimir Cmiljanovic, CEO of RocketVax, talked about developing safe and effective SARS-CoV-2 vaccine for PRVA TV

How come that first generation of SARS-CoV-2 vaccines may not provide high-level, long-term protection?
How do the vaccines compare?
What are the advantages of the second generation of the COVID-19 vaccine?
Are current vaccines effective and for how long?
How many shots do we need?

Our CEO, Dr. Vladimir Cmiljanovic, answered these and many more questions about the challenges of developing a safe and effective SARS-CoV-2 vaccine in RocketVax for PRVA TV:

In the process of developing our vaccine against SARS-CoV-2, our experts in RocketVax use coronavirus-based vectors that carry all the coronavirus’s immunogenic features but cannot reproduce, making the particles non-infectious.
A digital DNA design platform ensures the novel vaccine vectors’ easy design and streamlined production. Utilizing highly sophisticated algorithms, we have generated custom-designed synthetic viral genomes packed into attenuated yet authentic virus particles.
These particles can be continuously produced in a highly controlled process using well-characterized cell lines.

Follow our LinkedIn, Instagram, and Facebook page to keep up with our progress.

Share

22 April 2021

CEO of RocketVax, Dr. Vladimir Cmiljanovic, spoke to Watson about the development of a next-generation SARS-CoV-2 vaccine, RVX-13

“There is light at the end of the tunnel. Progress is being made in vaccines against SARS-CoV-2, if somewhat slowly, particularly in Switzerland. They promise a return to normality, though they are not without setbacks. The vector vaccines developed by AstraZeneca and Johnson & Johnson are under fire following cases of thrombosis in younger women. […]

21 April 2021

CEO of RocketVax, Dr. Vladimir Cmiljanovic, spoke to SRF 1 radio about next generation SARS-CoV-2 vaccine, RVX-13

Dr. Vladimir Cmiljanovic, CEO of RocketVax, gave an interview to Swiss SRF 1 radio about the progress of RVX-13 – a second-generation SARS-CoV-2 vaccine: Source: SRF 1 Radio The most important differences between RVX-13, RocketVax’s SARS-CoV-2 vaccine, and the first-generation vaccines are as follows: 1. RVX-13 induces a comprehensive activation of the immune system. Unlike […]

20 April 2021

Serbian “Telegraf” is reporting about RocketVax’s SARS-CoV-2 vaccine

When the ongoing coronavirus pandemic broke out at the start of 2020, Swiss Rockets AG set itself the challenge of manufacturing a vaccine that activates multiple lines of immune system defense to combat SARS-CoV-2 most effectively. To achieve this mission, it founded the Basel-based subsidiary RocketVax AG in the summer of 2020. To start working […]

09 April 2021

How come China controls the pandemic so effectively? How will the second-generation of SARS-CoV-2 vaccine, RVX-13, provide long-lasting immunity?

CEO of RocketVax, Dr. Vladimir Cmiljanovic, explains for Kanal 5 TV Macedonia his opinion on how China has managed to control the pandemic rapidly and effectively. During the interview, Dr. Cmiljanovic also talked about the development of the second-generation SARS-CoV-2 vaccine, RVX-13, that will provide long-lasting immunity. “The first reason is that the socialist system […]

16 March 2021

Dr. Vladimir Cmiljanovic: “RocketVax SARS-CoV-2 vaccine should be effective regardless of the mutation occurring on the spike protein”

CEO of RocketVax, Dr. Vladimir Cmiljanovic, gave an interview about the development of the second-generation SARS-CoV-2 vaccine for RTS (Serbian Broadcasting Corporation). “The first-generation vaccines are focused on one of the virus’s proteins – the so-called spike protein. They train our immune system by exposing the coronavirus spike protein to our immune cells. The so […]